Vir Biotechnology
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases....
Latest News
4 days ago · businesswire.com
Vir Biotechnology Announces Pricing of Public Offering of Common StockSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, be.
4 days ago · businesswire.com
Vir Biotechnology Announces Proposed Public OfferingSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares.
6 days ago · marketbeat.com
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48Vir Biotechnology NASDAQ: VIR said its combination treatment for chronic hepatitis delta met the primary and key secondary endpoints in the pivotal Phase III ECLIPSE 1 trial, with 79% of treated patients achieving undetectable virus at 48 weeks.
6 days ago · seekingalpha.com
Vir Biotechnology: Fairly Valued After Phase 3 Success?Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. VIR's Hepatitis Delta therapy achieved 44% primary endpoint success and 79% undetectable virus rates, with a strong safety profile and no discontinuations. With $991.3 million in cash, a $5.79 per-share cash floor, and funding secured into H2 2028, downside risk is limited.
8 days ago · seekingalpha.com
Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data TranscriptVir Biotechnology, Inc. ( VIR ) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data November 9, 2026 8:30 AM EST Company Participants Kiki Patel - Head of Investor Relations Marianne De Backer - President, CEO & Director Conference Call Participants Cory Kasimov - Evercore ISI Institutional Equities, Research Division Philip Nadeau - TD Cowen, Research Division Alec Stranahan - BofA Securities, Research Division Frank Wang Zhong - Leerink Partners LLC, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Cynthia Garcia Joseph Stringer - Needham & Company, LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Presentation Operator Hello, and welcome to Vir Biotechnology's ECLIPSE 1 Pivotal Phase 3 Topline Results and SOLSTICE Finite Treatment Conference Call. As a reminder, this call is being recorded.
8 days ago · investors.com
Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D TreatmentVir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.
8 days ago · zacks.com
Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should KnowThe mean of analysts' price targets for Vir Biotechnology (VIR) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
8 days ago · gurufocus.com
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment DataVir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of eleb
8 days ago · gurufocus.com
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis DeltaVir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous adminis
12 days ago · marketbeat.com
What Vir Biotechnology (VIR) Said on Its Q3 Earnings CallVir Biotechnology NASDAQ: VIR expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 2027, executives said on the company's third-quarter earnings call.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VIR